Bod Science (ASX:BOD) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:BOD Bod Science Ltd ASX:BOD
12 GF Score
Price A$0.02
GF Value A$0.04
! 3 Warning Signs
View Full Analysis

What is Bod Science 5-Year EBITDA Growth Rate?

Bod Science ASX:BOD 12 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2025. GuruFocus rates ASX:BOD with a GF Score™ of 12/100 and a GF Value™ of A$0.04. The stock has 3 warning signs investors should review.

Bod Science's EBITDA per Share for the six months ended in Jun. 2025 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bod Science was 13.10% per year. The lowest was 2.30% per year. And the median was 11.40% per year.

Bod Science  (ASX:BOD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Bod Science 5-Year EBITDA Growth Rate Related Terms

ASX:BOD vs ZTS: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bod Science 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bod Science's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bod Science's 5-Year EBITDA Growth Rate falls into.


ASX:BOD
12GF Score
Bod Science Ltd ASX:BOD
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bod Science 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Bod Science (ASX:BOD) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bod Science and its competitors.
Is Bod Science's 5-Year EBITDA Growth Rate too high?
Bod Science's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's 5-Year EBITDA Growth Rate compare to ZTS?
Bod Science's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bod Science and its competitors. Bod Science's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current 5-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bod Science (ASX:BOD) Overvalued in 2026?

Based on GuruFocus' analysis, Bod Science stock appears to be undervalued. The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.

Key valuation signals for ASX:BOD:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bod Science Business Description

Address C/- Rodgers Reidy, 210 Clarence Street, Level 12, Sydney, NSW, AUS, 2000
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score

Get the complete analysis for ASX:BOD

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.02
Price
A$0.04
GF Value